New Drug Application (NDA)

New Drug Application (NDA) represents the comprehensive regulatory submission to the United States Food and Drug Administration requesting approval to market a new pharmaceutical product, containing all data from preclinical studies, clinical trials, manufacturing processes, labelling, and other information necessary for regulatory review determining whether the drug is safe and effective. This pivotal regulatory milestone culminates years of research and development investment.

The NDA dossier encompasses clinical data from Phase I, II, and III trials demonstrating efficacy and characterising safety, preclinical pharmacology and toxicology studies, chemistry manufacturing and controls information detailing drug substance and product manufacturing, plus proposed labelling communicating approved uses, dosing, warnings, and prescribing information. FDA review employs multidisciplinary teams evaluating submitted data, with review timelines ranging from six months for priority review to ten months for standard review. Advisory committee meetings sometimes provide external expert input on controversial applications. Approval decisions balance demonstrated benefits against identified risks. Post-approval commitments often include additional studies confirming efficacy in specific populations. As regulatory science evolves incorporating real-world evidence and accelerated pathways, NDA submissions become increasingly sophisticated while maintaining rigorous standards.